According to filings with the U.S. Securities and Exchange Commission, Unicycive Therapeutics is raising up to $50,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Shalabh Gupta played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Unicycive Therapeutics
Unicycive Therapeutics invent and develop medications that help kidney patients feel their best and enjoy the best possible quality of life. At Unicycive, we know we’re all parts of a bigger whole. And we know that only together can we transform the landscape of healthcare to make the largest impact for the most amount of patients. MISSION: To build the world’s most advanced biotechnology system for finding, refining, and commercializing promising disease-modifying therapies quickly and efficiently.

To learn more about Unicycive Therapeutics, visit http://unicycive.com/

Contact:
Shalabh Gupta, Chief Executive Officer
650-351-4495
https://www.linkedin.com/in/shalabhgupta/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.